Peptide Regulatory News

Latest updates on FDA actions, state regulations, legal cases, and international developments affecting peptide laws.

Trial Update August 4, 2026

Phase 3 Trial to Compare Two Cagrilintide Versions and Placebo Registered

A new Phase 3 trial, NCT07745504, comparing two injectable cagrilintide versions and placebo in people with excess body weight was registered, dated Aug 4, 2026.

Read Full Article

All News

Trial Update August 4, 2026

Exenatide Pancreatic Cancer Safety Study Remains Recruiting

A pan-European post-authorisation safety study on exenatide and pancreatic cancer risk in type 2 diabetes patients is recruiting as of August 2026.

Trial Update August 4, 2026

Glucagon Featured in Metabolism Research Validation Trial (NCT06286761)

A trial involving glucagon, titled Routine Validation and Reproducibility Testing of Laboratory Measures and Research Techniques Used for Metabolism Research, is recruiting as of Aug 4, 2026.

Trial Update August 4, 2026

Glucagon-Related Trial "GLP-1 Use in Pregnancy" Now Recruiting

A new trial, "Gestational Response, Outcomes, and Weight After GLP-1 Use," began recruiting as of August 4, 2026, per ClinicalTrials.gov.

Trial Update August 4, 2026

Phase 1 Trial of Gonadorelin-Related Zoladex Now Recruiting

A Phase 1 trial evaluating subcutaneous ZOLADEX 10.8 mg for ovarian suppression in HR+, HER2- advanced breast cancer began recruiting as of Aug 4, 2026.

Trial Update August 4, 2026

Oxytocin-Related Trial on Digital Prenatal Education Registered

A new trial, "Digital Prenatal Education to Reduce Fear of Childbirth in Term Pregnancy," was registered on 2026-08-04 and is not yet recruiting.

Trial Update August 4, 2026

Semaglutide Phase 2 Trial in Type 1 Diabetes Obesity Recruiting

A Phase 2 trial testing semaglutide, a GLP-1 analogue, for obesity complicating type 1 diabetes is now recruiting, per an update dated August 4, 2026.

Trial Update August 4, 2026

Survodutide Trial NCT05202353 Now Active, Not Recruiting

A Phase 1 trial comparing survodutide (BI 456906) to semaglutide on liver glucagon receptor activity is active, not recruiting, as of Aug 4, 2026.

Trial Update August 4, 2026

Survodutide Phase 1 Formulation Comparison Trial Completed

A Phase 1 trial comparing two survodutide formulations in healthy volunteers completed as of Aug 4, 2026, per ClinicalTrials.gov.

Trial Update August 4, 2026

Tirzepatide Post-Bariatric Trial GRABS Now Active, Not Recruiting

Update on Aug 4, 2026: the GRABS Phase 2/3 pilot trial of tirzepatide after bariatric surgery is active but no longer recruiting participants.

Trial Update August 4, 2026

Triptorelin Featured in Phase 3 Breast Cancer Trial Update (NCT05879926)

A Phase 3 trial involving triptorelin for ovarian function suppression in premenopausal breast cancer patients is recruiting as of Aug 4, 2026.

Trial Update August 3, 2026

Cagrilintide Phase 3 Trial in Overweight/Obesity and Type 2 Diabetes Now Active

A Phase 3 trial of cagrilintide for weight loss in people with overweight or obesity and type 2 diabetes is now active but not recruiting, as of Aug 3, 2026.

Trial Update August 3, 2026

Gonadorelin Trial NCT07340619 Registered, Not Yet Recruiting

A new Phase 2 trial involving gonadorelin, NCT07340619, was registered on 2026-08-03 and is not yet recruiting, per ClinicalTrials.gov.

Trial Update August 3, 2026

Ibutamoren (LUM-201) Phase 3 Trial in Children Recruiting

A Phase 3 study of LUM-201, related to ibutamoren, in children with growth hormone deficiency is recruiting as of August 3, 2026, per ClinicalTrials.gov.

Trial Update August 3, 2026

Semaglutide Phase 4 Trial on Appetite and Eating Behavior Completed

A Phase 4 trial studying semaglutide's long-term effects on appetite and eating behavior was marked completed on Aug 3, 2026, per ClinicalTrials.gov.

Trial Update August 3, 2026

Somatostatin-Related Trial NCT06991738 Registered, Not Yet Recruiting

A Phase 1/2 trial testing 177Lu-DOTA-EB-TATE in Hurthle-cell thyroid cancer patients was registered, with status listed as not yet recruiting as of Aug 3, 2026.

Trial Update August 3, 2026

Thymosin Alpha-1 NSCLC Trial (NCT06139419) Marked Completed

A Phase 2 trial testing thymosin alpha-1 in locally advanced NSCLC patients undergoing chemoradiotherapy and immunotherapy consolidation is now listed as completed.

Trial Update August 3, 2026

Tirzepatide Phase 3 Trial in Heart Failure Patients With Obesity Registered

A Phase 3 trial evaluating tirzepatide in reduced ejection fraction heart failure patients with obesity was registered August 3, 2026, listed as not yet recruiting.

Trial Update July 31, 2026

Goserelin: Phase 3 Trial Update on Exemestane Plus Entinostat Reported

A phase 3 trial tracking goserelin, evaluating exemestane with or without entinostat in HR-positive breast cancer, is active but not recruiting as of July 31, 2026.

Trial Update July 31, 2026

Tirzepatide Phase 4 Trial "Fibrosis Lessens After Metabolic Surgery" Recruiting

A Phase 4 trial involving tirzepatide, titled "Fibrosis Lessens After Metabolic Surgery," is recruiting as of July 31, 2026, per ClinicalTrials.gov.

Trial Update July 31, 2026

Trial Studying Vagus Nerve Stimulation for Tirzepatide Poor Response Recruiting

A clinical trial examining transcutaneous auricular vagus nerve stimulation for poor weight-loss response to incretin receptor agonists is now recruiting, per a 2026-07-31 update.